Benefiting from the new listing chapter, Hong Kong has become the second largest and a leading biotech fundraising hub globally. In March this year, ChinaAMC (HK) 華夏基金(香港) listed the first purely Hong Kong-listed names BioTech ETF (3069. HK), further unveiling a new era for HK Biotech industry. Wanna Grasp this golden investment opportunity and follow frontier dynamics of the sector?

Now you have a good chance. We are pleased to announce that we will invite Daniel Mak, VP of Business Development of ChinaAMC (HK) to have a webinar with Lester Chan, our Head of Wealth Management in Greater China, to dive-in unique opportunities in BioTech investment.

Additionally, do you want to know what are Cathie Wood’s newest strategies and her investment tricks? Find it in this webinar! Daniel will recap key takeaways from the Leadership Dialogue between Cathie Wood (CEO & CIO of ARK Invest) and Yimei Li (CEO of ChinaAMC).